Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study

Background: Optimal use of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis is vital if progression of disease is to be reduced. Methotrexate (MTX) and sulfasalazine (SASP) are widely used inexpensive DMARDs, recently often combined despite no firm evidence of benefit from previous studies. Aim: To establish whether a combination of SASP and MTX is superior to either drug alone in patients with rheumatoid arthritis with a suboptimal response to 6 months of SASP. Methods: A randomised controlled study of step-up DMARD treatment in early rheumatoid arthritis. In phase I, 687 patients received SASP for 6 months. Those with a disease activity score (DAS) ⩾2.4 were offered additional treatment in phase II (SASP alone, MTX alone or a combination of the two). The primary outcome measure was change in DAS. Results: At 6 months, 191 (28%) patients had a DAS <2.4, 123 (18%) were eligible but did not wish to enter phase II, 130 (19%) stopped SASP because of reversible adverse events and 165 (24%) entered phase II. DAS at 18 months was significantly lower in those who received combination treatment compared with those who received either SASP or MTX: monotherapy arms did not differ. Improvement in European League Against Rheumatism and American College of Rheumatology 20, 50 and 70 scores favoured combination therapy. Conclusions: In this “true-to-life” study, an inexpensive combination of DMARDs proved more effective than monotherapy in patients with rheumatoid arthritis with a suboptimal response to SASP. There was no increase in toxicity. These results provide an evidence base for the use of this combination as a component of tight control strategies.

[1]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[2]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[3]  K. Winthrop.  Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor α , 2005, Annals of the rheumatic diseases.

[4]  E. Keystone,et al.  Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? , 2005, Arthritis and rheumatism.

[5]  P. V. van Riel,et al.  The Disease Activity Score and the EULAR response criteria. , 2005, Clinical and experimental rheumatology.

[6]  D. Symmons.  Anti-tumour necrosis factor α therapy: can we afford it? , 2005 .

[7]  L. Jacobsson,et al.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists , 2005, Annals of the rheumatic diseases.

[8]  L. Jacobsson,et al.  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists , 2005, Annals of the rheumatic diseases.

[9]  M. Dougados,et al.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. , 2004, Annals of the rheumatic diseases.

[10]  M. Dougados,et al.  When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? , 2004, Annals of the rheumatic diseases.

[11]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[12]  B. Dijkmans,et al.  Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[13]  J. Stoner,et al.  Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[14]  J. O'dell,et al.  Treating rheumatoid arthritis early: a window of opportunity? , 2002, Arthritis and rheumatism.

[15]  Rene Westhovens,et al.  COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. , 2002, Arthritis and rheumatism.

[16]  F. Wolfe,et al.  Premature mortality in patients with rheumatoid arthritis: evolving concepts. , 2001, Arthritis and rheumatism.

[17]  P. Hannonen,et al.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial , 1999, The Lancet.

[18]  M. Dougados,et al.  Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components , 1999, Annals of the rheumatic diseases.

[19]  D. Felson,et al.  ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. , 1999, The Journal of rheumatology.

[20]  T. Treasure,et al.  Minimisation: the platinum standard for trials? , 1998, BMJ.

[21]  P. Tugwell,et al.  Combination therapy in rheumatoid arthritis: updated systematic review. , 1998, British journal of rheumatology.

[22]  L. V. D. van de Putte,et al.  Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. , 1997, British journal of rheumatology.

[23]  S. van der Linden,et al.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis , 1997, The Lancet.

[24]  J. O'dell,et al.  Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. , 1996, The New England journal of medicine.

[25]  P. Tugwell,et al.  Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. , 1995, The New England journal of medicine.

[26]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[27]  L. V. D. van de Putte,et al.  Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. , 1994, British journal of rheumatology.

[28]  D. Felson,et al.  The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. , 1994, Arthritis and rheumatism.

[29]  J. Hunter,et al.  Combination therapy in rheumatoid arthritis--no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. , 1993, The Journal of rheumatology.

[30]  M. A. van 't Hof,et al.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. , 1990, Annals of the rheumatic diseases.

[31]  D. M. van der Heijde,et al.  How to read radiographs according to the Sharp/van der Heijde method. , 2000, The Journal of rheumatology.

[32]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.